
Full Ablation Making a Comeback in Energy-Based Medicine
ORLANDO, Fla. — For years, fully ablative laser skin resurfacing — in which the epidermis is removed using carbon dioxide or erbium lasers — fell out of favor among energy-based medicine specialists and their patients because of long recovery times and the need for general anesthesia.
Fractional ablative laser resurfacing, a less invasive procedure that makes tiny holes in the epidermis and leaves surrounding skin intact, became more popular, along with nonablative collagen-stimulating treatments.
But at The American Society for Laser Medicine and Surgery (ASLMS) 2025 Annual Meeting, held from April 24 to 26, several presenters spoke about a 'resurgence' of the full ablation approach.
They cited two reasons: First, results from fractional treatments have not been as dramatic or durable as hoped for, especially in older patients, and second, newer laser technologies are allowing for ablation to be performed without general anesthesia and with healing times closer to those seen with less-invasive treatments.
Echoing many of his colleagues at the conference, Oculofacial Surgeon Brian Biesman, MD, of Vanderbilt University, who is in private practice in Nashville, Tennessee, said that in recent years he has returned to performing fully ablative procedures after having given them a rest.
'The moment for me was when I saw a patient who I knew I had seen several years before,' Biesman said in an interview. 'I didn't remember what [procedure] I had done, and I thought she needed laser resurfacing. I opened her chart and realized that I had done fractional ablative resurfacing on her 3 years before. That was when I decided that for what we put people through, they need to have a better result than this 3 years later. I decided to get back to more aggressive approaches.'
Dermatologic Surgeon Thomas Rohrer, MD, who is in private practice in Chestnut Hill, Massachusetts, said in an interview that to treat deeper lines, especially in certain parts of the face, 'we're coming to a consensus that we need that more aggressive treatment. That's why you're seeing a lot of talks this year about fully ablative devices. But with that comes the risks associated with it and the downtime.'
Ablative Therapy With Less Pain and Shorter Recovery
While ablative procedures using time-tested technologies — CO2 and erbium lasers — are also making a comeback, Rohrer and other specialists pointed to a newer device that they described as a game changer: The UltraClear 2910 nm cold ablative fractional laser, cleared by the US Food and Drug Administration in 2022 to treat photoaging, wrinkles, and acne scars, which has since seen its indications expanded to include some types of pigmented lesions.
The device can be used on fractional ablative or fully ablative settings. It does not heat tissue the way traditional ablative lasers do. This results in reduced pain and shorter recovery time, and offers additional protection against hypo- and hyper-pigmentation, a key concern with darker skin types.
The 2910 nm laser 'has really revitalized our resurfacing practice in patients aged 50 to 80,' said Paul Friedman, MD, who is in private practice in Houston, 'because of the patient comfort and the quicker recovery process,' which can be as little as a week compared with a month or more for other technologies.
Ablative procedures with the 2910 nm laser usually require only 'topical anesthesia and occasional nitrous oxide,' Friedman said at the meeting. 'Prior to this technology, with our traditional resurfacing modalities, we found it more efficient to bring in an anesthesiologist. But obviously there is hesitance from patients about this.'
Suzanne Kilmer, MD, a dermatologist at the University of California, Davis, California, who is also in private practice in Sacramento, California, and a widely recognized expert on full ablation, said that she was still getting to know the device. She has yet to use the 2910 nm laser for a fully ablative procedure, she said, sticking to its fractional settings.
'I use it in conjunction with the traditional erbium and CO2 lasers,' Kilmer said in an interview, adding that she is fine with going slow for now. 'There always is a learning curve with devices,' she cautioned. 'And you're learning on risky procedures.'
Preventing and Mitigating Complications
Full ablation 'is a great procedure — there's nothing else like it,' Kilmer continued. But unlike with fractional treatments, it also means that 'you've taken off the whole top of the skin. There's a huge open wound. You've completely disrupted the dermal-epidermal junction.'
During different seminars at the conference, experts offered strategies for avoiding treatment-related complications, including hypo- and hyper-pigmentation, scarring, and infections. They spoke about selecting the patients who are likely to comply with demanding aftercare protocols, highlighting how they rescued cases in which patients did not.
And they shared horror stories of patients who went kayaking 3 days after ablative treatment, accidentally vomited on their wounds, who developed severe erythema or scarring, or developed serious infections despite the use of antiviral and antibiotic prophylaxis. With some of these complications, practitioners acknowledged that there is little consensus on how they should be managed.
Jacqueline Watchmaker, MD, a dermatologist in private practice in Scottsdale, Arizona, reviewed the case of a patient who developed a severe bacterial infection following ablation because of noncompliance with aftercare recommendations. It is important to know how soon infections are likely to appear, Watchmaker said, and to be aware of signs — especially pain that increases over days. It's also important to select patients carefully for their likelihood of complying, she added.
Other presenters discussed ways to improve compliance, such as by making video tutorials.
Dermatologist Arisa Ortiz, MD, director of Laser and Cosmetic Dermatology, at UC San Diego Health, San Diego, and the past president of ASLMS, warned that even with antibiotic and antiviral prophylaxis, patients can develop breakthrough infections requiring emergency treatment. The right type of antibiotic prophylaxis remains controversial in fully ablative resurfacing, she noted. Any apparent infections should be cultured before treating them and systemic infections, requiring hospital treatment, can occur.
Biesman, in his comments, agreed that antibiotic prophylaxis remains a controversial topic with ablative resurfacing. 'The argument from infectious disease is that you don't need antibiotic prophylaxis,' he told the conference, but in practice it is standard. And while many clinicians use cefalexin, which does not prevent infections from methicillin-resistant Staphylococcus aureus , or MRSA, 'you really need to think about MRSA coverage' when prescribing an antibiotic, he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
US-led scientists discover new evidence on origins of intermediate-mass black holes
Black holes are generally grouped into three sizes: stellar-mass black holes, which are about five to 50 times the mass of the sun; supermassive black holes, with millions to billions of times the sun's mass; and intermediate-mass black holes, which fall somewhere in between. Four new studies have brought fresh insight into the mystery of intermediate-mass black holes. The research was led by Assistant Professor Karan Jani, founding director of the Vanderbilt Lunar Labs Initiative, with funding from the National Science Foundation and Vanderbilt University. The main study, titled "Properties of 'Lite' Intermediate-Mass Black Hole Candidates in LIGO-Virgo's Third Observing Run," was published in Astrophysical Journal Letters, with the team reexamining data from the LIGO detectors in the U.S. and the Virgo detector in Italy. They found that the detected gravitational waves came from mergers of black holes weighing between 100 and 300 times the mass of the sun, marking the largest black hole collisions ever recorded. According to Jani, black holes are like cosmic fossils that hold clues to the early universe. The newly identified group of black holes, revealed in this analysis, provides a unique opportunity to learn more about the very first stars that formed after the Big Bang. Earth-based detectors like LIGO can only catch a brief moment of the final collision of these 'lighter' intermediate-mass black holes, making it hard to understand how they form. To learn more, Jani's lab is focusing on the upcoming LISA mission—a space-based project by the European Space Agency and NASA set to launch in the late 2030s. Two additional studies published in the Astrophysical Journal demonstrated that the upcoming LISA mission can track intermediate-mass black holes years before they merge, providing new insights into their origins, evolution, and fate. The research also highlighted how detecting gravitational waves requires extreme precision—comparable to hearing a pin drop during a hurricane. The researchers noted that this work supports the idea that intermediate-mass black holes are among the most important sources for gravitational-wave detectors, both on Earth and in space. Each new detection helps scientists better understand where these black holes come from and why they exist within this unusual mass range. Looking ahead, the team plans to investigate how detectors on the moon could help observe intermediate-mass black holes in the future. Access to lower gravitational-wave frequencies from the lunar surface could help identify the environments where these black holes exist—something that Earth-based detectors cannot achieve. The scientist pointed out that this is an exciting time, not only for studying black holes but also for combining scientific research with the new era of space and lunar exploration. It presents a rare chance to train the next generation of students whose discoveries will be influenced by, and conducted from, the moon, Jani added.
Yahoo
3 days ago
- Yahoo
Acclaro Medical secures $23m in Series B funding for skin laser technologies
Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear and AuraLux, and facilitate the company's global market expansion. Accelmed Partners spearheaded the funding round, which also received support from the current investor, 3E Bioventures Capital. Acclaro Medical co-founder and CEO Helen Fang said: "This funding empowers us to continue our strong growth and realise our vision of improving the quality of life for people of all skin colours and all ages worldwide." UltraClear comprises a 2,910nm cold ablative fibre laser that leverages 3DIntelliPulse technology and offers enhanced safety across all types of skin. Cleared by the US Food and Drug Administration (FDA), UltraClear operates by vaporising the skin's damaged outer layers and heating the underlying layers with controlled thermal energy, promoting the growth of new cells and boosting elastin and collagen production. According to Acclaro Medical, the laser's cold beams aid in the removal of damaged epidermal cells, reducing side effects and pain. Its beam quality facilitates consistent resurfacing outcomes, akin to an advanced form of exfoliation. Alongside UltraClear, the company's AuraLux laser utilises the exclusive Cool Pulse technology. This expansion of the product line aims to enhance accessibility for providers and their patients. Acclaro Medical co-founder and president Shlomo Assa said: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-ageing solutions for healthier and younger-looking skin. 'It greatly enables us to accelerate product development, expand our team, and reach more customers globally." In 2022, Acclaro Corporation introduced the UltraClear laser technology system in the US. "Acclaro Medical secures $23m in Series B funding for skin laser technologies" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
4 days ago
- Yahoo
Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced promising results from its Phase 2 trial of NBI-1117568, a first-in-class investigational oral muscarinic M4 selective agonist for schizophrenia. Presented at the American Society of Clinical Psychopharmacology 2025 Annual Meeting, the study showed that a 20 mg once-daily dose significantly improved schizophrenia symptoms, achieving a 7.5-point greater reduction on the Positive and Negative Syndrome Scale (PANSS) than placebo at six weeks. Improvements were also seen on the Clinical Global Impression of Severity (CGI-S) scale as early as Week 2, with continued benefit through Week 6. A scientist studying the effects of neurotrophic factors on neuronal survival. NBI-1117568 was generally safe and well tolerated, with somnolence and dizziness as the most common side effects and no significant weight gain or clinically meaningful cardiovascular events. Discontinuation rates due to adverse events were similar to placebo. Higher doses showed greater mean improvements but did not reach statistical significance. These results have prompted Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to launch a global Phase 3 trial to further evaluate the drug's efficacy and safety in adults with acute schizophrenia symptoms. NBI-1117568's novel mechanism offers hope for a more targeted and tolerable treatment option for patients. While we acknowledge the potential of NBIX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NBIX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data